Century Therapeutics Inc (IPSC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Century Therapeutics Inc (IPSC) has a cash flow conversion efficiency ratio of -0.101x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.08 Million) by net assets ($158.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Century Therapeutics Inc (IPSC) balance sheet quality index to measure how much of total assets are equity-financed.
Century Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Century Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IPSC cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Century Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Century Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CJ Corp 4P Pref
KO:00104K
|
0.102x |
|
Cheng Mei Materials Technology Corp
TW:4960
|
0.050x |
|
Ve Wong Corp
TW:1203
|
0.048x |
|
ROUTE MOBILE LIMITED
NSE:ROUTE
|
0.015x |
|
AVI Japan Opportunity Trust PLC
LSE:AJOT
|
0.000x |
|
Bigcommerce Holdings Inc
NASDAQ:BIGC
|
0.350x |
|
Fusion Micro Finance Limited
NSE:FUSION
|
0.221x |
|
CARYSIL LIMITED
NSE:CARYSIL
|
0.116x |
Annual Cash Flow Conversion Efficiency for Century Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Century Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see IPSC company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $158.94 Million | $-103.88 Million | -0.654x | +4.24% |
| 2024-12-31 | $161.36 Million | $-110.14 Million | -0.683x | -42.73% |
| 2023-12-31 | $184.75 Million | $-88.35 Million | -0.478x | -1130.25% |
| 2022-12-31 | $302.74 Million | $14.05 Million | 0.046x | +120.66% |
| 2021-12-31 | $396.24 Million | $-89.00 Million | -0.225x | -157.92% |
| 2020-12-31 | $-106.41 Million | $-41.27 Million | 0.388x | +120.34% |
| 2019-12-31 | $-91.86 Million | $-16.17 Million | 0.176x | -39.30% |
| 2015-12-31 | $359.71 Million | $104.30 Million | 0.290x | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more